Community health centers on Tuesday split their 340B dispute resolution petition against drug manufacturers Eli Lilly, Sanofi, and AstraZeneca into two—one against Lilly alone, the other against Sanofi and AstraZeneca together—to let federal officials commence proceedings against Sanofi and AstraZeneca. When or even whether ADR proceedings against the two companies begin is unknown.
In March, a federal district judge granted Lilly’s motion for a preliminary injunction stopping the U.S. Health and Human Services Department (HHS) from initiating 340B administrative dispute resolution (ADR) proceedings against the company. The court ruled that Lilly was likely to win its argument that HHS violated notice-and-comment requirements when it finalized the rule establishing the ADR process.
Community health centers on Tuesday split their 340B dispute resolution petition against drug manufacturers Eli Lilly, Sanofi, and AstraZeneca into two—one against Lilly alone, the other against Sanofi and AstraZeneca together—to let federal officials commence proceedings against Sanofi and AstraZeneca.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
